Bristol-Myers Squibb (NYSE:BMY) Reports Bullish Q3

Bristol Myers Squibb's Q3 2025 results show a 3% revenue increase and a 7% earnings per share beat, with full-year revenue projections slightly above estimates. Despite overall sales growth lagging, the Growth Portfolio segment has seen stronger performance. However, analysts predict a 7% revenue drop in the next year, and while the company's operating margin is higher than the industry average, profit growth may face challenges.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.